Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Lucid Group

Peloton

Investors need to understand and be able to steer clear of companies that have a poor future outlook. Whether from reduced financial guidance, overall financial instability, management issues, or relevancy surrounding their product and or services.

Don't Waste Another Minute: Dump These 3 F-Rated Stocks Now

Is Moderna stock a buy after announcing promising results for its Merck-tied cancer vaccine? Is MRNA stock a buy right now?

Is Moderna Stock A Buy After Retaking Its 50-Day Line On Strong Cancer Vaccine Sales?

BioNTech SE

JD.com

BioNTech's pipeline should take center stage going forward. JD.com is dirt cheap after a big sell-off.

3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024

Investors have shied away from buying Moderna shares as demand for its coronavirus vaccine declines. But the biotech has set high goals, aiming to release many new products during the next few years.

Moderna Just Took a Step Closer to Its Product Launch Goal. Is the Stock a Buy?

Occidental Petroleum

Sunrun

The bulls look to be firmly in control of the stock market now. The U.S. Federal Reserve has pivoted away from its monetary tightening regime and signaled three interest rate cuts in 2024.

3 S&P 500 Stocks That Are About to Get Absolutely Crushed

Moderna and Merck reported data regarding their cutting-edge mRNA-based skin cancer regimen that includes the former's cancer vaccine, MRNA-4157. This mRNA-based skin cancer regimen represents one of Moderna's pipeline programs diversifying the company's portfolio and potentially shaping its future beyond the pandemic. The positive outcomes from the MRNA-4157 trial contribute to a bullish outlook for Moderna, demonstrating its capacity to innovate and excel in the field of oncology.

Moderna: MRNA-4157 Cancer Vaccine Data Points To A Future Beyond Spikevax

U.S. drug regulators in September found quality control lapses at Moderna's main factory including with equipment used to manufacture drug substance for its COVID-19 vaccine, according to the report obtained by Reuters via a Freedom of Information Act request.

Exclusive: US FDA finds control lapses at Moderna manufacturing plant

Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.

Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study

Moderna Inc.'s MRNA, +9.25% investigational vaccine for respiratory syncytial virus is 84% effective against the lower respiratory tract illness linked with the virus, according to phase 3 study data published in the New England Journal of Medicine. The vaccine, which uses the mRNA technology also used in COVID shots, was studied in adults 60 years of age and older and resulted in no evident safety concerns, the study found.

Moderna RSV vaccine more than 80% effective, study shows

Moderna has submitted marketing authorizations globally for mRNA-1345 and continues to prepare for an expected 2024 marketing launch CAMBRIDGE, MA / ACCESSWIRE / December 15, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced the publication of positive Phase 3 clinical study results evaluating mRNA-1345, its vaccine candidate for respiratory syncytial virus (RSV), in The New England Journal of Medicine . The peer-reviewed article summarizes safety and efficacy data from ConquerRSV, the Company's Phase 2-3 trial evaluating mRNA-1345.

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company's Investigational Respiratory Syncytial Virus (RSV) Vaccine

Abbott Labs

Pfizer

Investors loved these stocks earlier in the pandemic -- but they've since fallen out of favor. They actually make terrific long-term buys, though, and today you can pick them up for a steal.

3 No-Brainer Healthcare Stocks to Buy Right Now

Merck

Moderna (NASDAQ: MRNA ) has been on a rough trajectory in recent days. Indeed, continuous declines in MRNA stock earlier this week have hurt investor sentiment in the large-cap biotechnology company.

MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer

A personalized vaccine developed by Moderna (MRNA) and Merck (MRK) showed significant positive results in treating skin cancer in high risk patients.

Moderna-Merck Vaccine for Skin Cancer Shows Positive Results; Moderna Stock Jumps

Adobe

U.S. equities were up at midday, with the Dow adding to its record high set yesterday, as rising retail sales added to enthusiasm surrounding the Federal Reserve's comments signaling rate cuts next year. The S&P 500 and Nasdaq were up as well.

Midday Movers: Moderna Soars on Vaccine Trial, Adobe Slumps on Guidance Miss

Moderna Therapeutics Inc (NASDAQ:MRNA) revealed positive data from its second cut of the cancer vaccine for adjuvant melanoma in combination with Keytruda. The report indicates a 49% recurrence-free survival (RFS) benefit, an improvement from the previous 44%.

Moderna's cancer vaccine shows promise, but regulatory hurdles loom

Moderna's new mRNA vaccine reduces the chance of relapse or death of skin cancer by half when paired with Merck's immunotherapy drug Keytruda, new data shows, marking a step forward in the developing field of mRNA technology and sending Moderna's stock soaring Thursday morning.

Moderna Stock Soars After Cancer Vaccine's Strong Test Results

Moderna Inc  (NASDAQ:MRNA) stock was last seen up 15.4% to trade at $90.72, one of the best stocks on the Nasdaq today, after data from a mid-stage trial showed the company's experimental cancer vaccine with Merck (MRK), combined with immunotherapy Keytruda, helped melanoma patients reduce the risk of death or relapse after three years.

Moderna Stock on Track for Best Day Since 2022

Moderna Inc (NASDAQ: MRNA) is up nearly 15% this morning after reporting mid-stage trial data for its experimental vaccine for skin cancer.

Moderna stock popped 15% on Thursday: explore why

Stocks continued to move higher following the Federal Reserve's latest decision. Adobe shares fell as strong financial results weren't enough to overcome worries about future growth.

2 Big Stocks Making Big Moves Thursday

Moderna (NASDAQ: MRNA ) stock is rising thanks to positive results from the skin cancer vaccine developed alongside Merck (NYSE: MRK ). The big news here comes after a Phase 2b trial of mRNA-4157 as an investigational individualized neoantigen therapy while combined with KEYTRUDA.

Why Is Moderna (MRNA) Stock Up 11% Today?

Carisma Therapeutics Inc

First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility, tolerability and early efficacy of in vivo CAR-M therapy utilizing mRNA/LNPs in solid tumors PHILADELPHIA , Dec. 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need.

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

Moderna Inc.'s stock MRNA, +0.72% soared 7% early Thursday, after the biotech and partner Merck MRK, +2.65% announced positive data from a mid-stage trial of Moderna's mRNA-4157 in combination with Merck's blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV). The companies said after about three years, the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%, compared with Keytrua alone.

Moderna's stock rallies 7.9% after announcing positive data in trial of melanoma treatment combined with Merck's Keytruda

An experimental messenger RNA cancer vaccine developed by Moderna and Merck & Co paired with Merck's Keytruda cut the chance of recurrence or death from melanoma by half after three years, showing that benefits demonstrated a year ago have held up over time.

Benefits of Moderna and Merck melanoma vaccine plus Keytruda extend to three years

Moderna's Merck-partnered cancer vaccine reduced the risk of relapse or death by 49% in melanoma patients. Moderna stock could jump.

Moderna's Cancer Vaccine Cuts Risk Of Relapse, Death By 49%; Will Shares Jump?

At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis or death by 62% (HR=0.384 [95% CI, 0.172-0.858]; one-sided nominal p= 0.0077) compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection Data builds on the primary analysis reported at AACR and ASCO in 2023, which showed that mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% and reduced the risk of distant metastasis or death by 65% at a median planned follow-up of approximately two years Companies have initiated Phase 3 studies in the adjuvant setting in patients with high-risk melanoma and non-small cell lung cancer and plan to rapidly expand to additional tumor types CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / December 14, 2023/ Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV) following complete resection. In this planned analysis occurring with a median follow-up of approximately three years, adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA continued to demonstrate a clinically meaningful improvement in recurrence-free survival (RFS), reducing the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) compared with KEYTRUDA alone.

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp

News for Moderna Stock (MRNA)